Yahoo!
My Yahoo!
Mail
Sign In
[New User?
Sign Up
]
Finance Home
|
Help
Wednesday, February 10, 2010, 3:05PM AEST - The Australian Stockmarket closes in 1 hour.
To create a watchlist or portfolio of shares,
Register
FINANCE HOME PAGE
INVESTING
FINANCE NEWS
PERSONAL FINANCE
SMALL BUSINESS
Enter symbol(s):
Symbol Lookup
|
Exchanges
Search News:
Omeros Corporation (OMER)
8:00AM AEST:
5.69 USD
0.13 (2.23%)
MORE ON OMER
Quotes
Summary
Options
Historical Prices
Charts
Basic Chart
Technical Chart
Technical Analysis
Detailed Data
News & Info
Headlines
Company Events
Company
Profile
Key Statistics
SEC Filings
Competitors
Industry
Analyst Coverage
Analyst Opinion
Analyst Estimates
Research Reports
Star Analysts
Ownership
Insider Trans.
Insider Roster
Financials
Income Statement
Balance Sheet
Cash Flow
Omeros Corporation
(NGM:OMER) Delayed quote data
Last Trade:
5.69 USD
Trade Time:
8:00AM AEST
Change:
0.13 (2.23%)
Prev Close:
5.82
Open:
5.83
Bid:
4.30
x 600
Ask:
N/A
1y Target Est:
11.80
Day's Range:
5.65 - 5.86
52wk Range:
5.27 - 9.49
Volume:
26,725
Avg Vol
(3m)
:
45,754
Market Cap:
121.04M
P/E
(ttm)
:
N/A
EPS
(ttm)
:
-7.48
Div & Yield:
N/A (N/A%)
1d
5d
3m
6m
Add OMER to Portfolio
Download Data
HEADLINES
Omeros Announces National Institute on Drug Abuse's Support for Phase 2 Clinical Study in Addiction Program
PR Newswire
(Fri, Jan 29)
After A Sluggish Year, VCs Eye Improvement
Investor's Business Daily
(Sat, Jan 9)
IPO comeback in 2009 sets stage for busy 2010
AP
(Fri, Jan 1)
The Worst IPOs Of 2009
at Investopedia
(Thu, Dec 17)
Worst IPOs of 2009: Biggest Stock Flops
at TheStreet.com
(Wed, Dec 16)
OMEROS CORP Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online
(Wed, Dec 9)
Coverage initiated on Omeros by Needham
Briefing.com
(Wed, Dec 2)
New Star Analyst Rankings for Omeros Corporation
StarMine
(Mon, Nov 23)
OMEROS CORP Files SEC form 8-K, Results of Operations and Financial Condition
EDGAR Online
(Fri, Nov 20)
Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
PR Newswire
(Fri, Nov 20)
More Headlines for OMER...
ANALYST
EPS Est (next year)
(Dec-09)
:
-1.44
EPS Est (in 2 years)
(Dec-10)
:
-1.41
Avg Rec (current)*:
1.6
PEG Ratio:
N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion
-
Estimates
BUSINESS SUMMARY
Omeros Corporation, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing products on inflammation and disorders of the central nervous system.
Full Company Profile
Add to Portfolio
Email to a Friend
Get
Summary
for Another Symbol:
Australia
New Zealand
US
----------------
Argentina
Austria
Brazil
Canada - Toronto
Canada - Vancouver
China - Shanghai
China - Shenzhen
Denmark
France
Germany XETRA
Germany - Berlin
Hong Kong
India - Bombay
India - National
Indonesia
Israel
Italy
Malaysia
Mexico
Netherlands
Norway
Singapore
South Korea - Korea
South Korea - KOSDAQ
Spain
Sweden
Switzerland
Taiwan OTC
Taiwan
Thailand
United Kingdom
Symbol Lookup
Latest News
7 Indices